Skip to main content
Premium Trial:

Request an Annual Quote

Bayer Tech Partners with CHOP on Software for Personalized Drug Dosing

NEW YORK (GenomeWeb News) - Bayer Technology Services is collaborating with Children’s Hospital of Philadelphia on a research project to develop individualized drug therapies for children, the company said today.
 
BTS will integrate its PK-Sim pharmacokinetic and pharmacodynamic modeling and simulation techniques with CHOP’s “Pediatric Knowledgebase” -- an initiative to create a user-friendly computer interface that will present doctors with patient information and dosing history and use simulations to predict “expected trends in drug plasma concentrations,” the company said.
 
The end result will allow pediatricians to make drug dosing decisions that are tailored to each patient, BTS said.
 
The collaboration will “aim to demonstrate the usefulness of physiology-based modeling in guiding dosing decisions.” said Jörg Lippert, Head of the Systems Biology Group of BTS, in a statement.

Filed under

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.